The entry of SARS-CoV-2 into its target cells depends on binding between the receptor-binding domain (RBD) of the viral spike protein and its cellular receptor, angiotensin-converting enzyme 2 (ACE2).1–3 The spike protein is highly immunogenic and the target of many neutralizing antibodies (NAbs).4 It has been demonstrated that convalescent blood samples obtained from individuals who recover from COVID-19 contain neutralizing activity,5 suggesting that humans are intrinsically capable of generating antibodies that potently neutralize SARS-CoV-2. The gene discussed is ACE2; the disease is COVID-19.